In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spectranetics promotes Hein and Boehme

This article was originally published in Clinica

Executive Summary

Spectranetics has promoted Jason Hein to senior vice-president of sales, marketing and product development for its vascular intervention and lead management businesses, and Renee Boehme to vice-president of US sales for the lead management unit. As part of this reorganisation, Mr Hein's previous role of vice-president and general manager, lead management, has been eliminated. Colorado Springs, Colorado-based Spectranetics' vascular intervention products include a range of laser catheters for ablating occluded arteries above and below the knee and within coronary arteries, as well as thrombus-removal aspiration catheters. Its lead management business sells excimer laser sheaths and cardiac lead management accessories for removing pacemaker and defibrillator cardiac leads.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel